Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

The present disclosure relates to compositions capable of absorbing UVA and UVB light. In particle, the present disclosure relates to UV screening compositions comprising at least a portion of LITE-1 polypeptides which are capable of absorbing UV light (e.g., UV-A and/or UV-B light).

The present invention relates to a modified neurotoxin single-chain polypeptide and a use thereof. The single-chain polypeptide contains a tagged protein, a linker short peptide, etc. The linker short peptide facilitates cleavage of the tagged protein, thereby improving purification of the single-chain polypeptide; in addition, the single-chain polypeptide has neurotoxicity when activated, but the single-chain polypeptide per se is only slightly toxic, such that the production safety is improved and the production process cost is reduced while the yield of the single-chain polypeptide is greatly increased.

The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding one or more cosmetic proteins (e.g., one or more human collagen proteins); viruses comprising the recombinant nucleic acids; compositions (e.g., cosmetic formulations) comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.

Disclosed herein is a method of preparing a subject's cells for topical treatment of a subject in need. Also provided is a topical formulation and methods of treating a subject suffering a skin disorder and pain using the topical formulation. Also disclosed herein are devices and systems for micronizing an aspirate in preparation of such a topical formulation.

The present invention relates to a method for proteolytically processing a single-chain clostridial neurotoxin into a corresponding di-chain clostridial neurotoxin, the method comprising: providing a single-chain clostridial neurotoxin; and contacting the single-chain clostridial neurotoxin with furin; wherein the single-chain clostridial neurotoxin has an activation loop comprising or consisting of the polypeptide sequence Arg-Xaa-Xaa-Arg; and wherein furin hydrolyses a peptide bond of the activation loop thereby producing a di-chain clostridial neurotoxin. The invention also relates to engineered clostridial neurotoxins and methods for manufacturing the same, as well as related pharmaceutical compositions, nucleotide sequences, and therapeutic and cosmetic uses.

The invention relates to a mixture composition comprising rhamnolipids, to a process for its preparation, to its use for producing formulations and to formulations comprising this mixture composition.

Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.

The present disclosure relates to compositions capable of absorbing UVA and UVB light. In particle, the present disclosure relates to UV screening compositions comprising at least a portion of LITE-1 polypeptides which are capable of absorbing UV light (e.g., UV-A and/or UV-B light).

The present disclosure relates to a recombinant BoNT/A and a preparation method thereof. The recombinant BoNT/A is a BoNT/A mutant, the BoNT/A mutant comprising a first peptide fragment and a second peptide fragment, which are linked through an interchain disulfide bond; wherein the first peptide fragment has a mutation at position 134 and/or position 165 compared to the light chain of a wild-type BoNT/A; and/or the second peptide fragment has at least one of the following mutation positions compared to the heavy chain of the wild-type BoNT/A: positions 791, 967, and 1060. The method includes: subjecting the first peptide fragment to a first renaturation treatment to obtain a first denatured product, subjecting the second peptide fragment to a second denaturation treatment to obtain a second denatured product, and subjecting the first denatured product and the second denatured product to a renaturation and assembly treatment to obtain the BoNT/A mutant.